| Zhou, Xin |
NCT05596721: Azithromycin Treatment for Non-eosinophilic Chest Tightness Variant Asthma |
|
|
| Not yet recruiting | 4 | 248 | RoW | Azithromycin, ICS/LABA | Second Affiliated Hospital, School of Medicine, Zhejiang University | Asthma, Chest Syndrome, Azithromycin, Effect of Drug | 03/24 | 03/24 | | |
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3 |
|
|
| Recruiting | 4 | 466 | RoW | Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638 | The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd. | Renal Insufficiency, Chronic | 10/25 | 03/26 | | |
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 85 | RoW | Pomalidomide, Dexamethasone | Qilu Pharmaceutical Co., Ltd. | Multiple Myeloma, Recurrent or Refractory | 06/22 | 12/23 | | |
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 |
|
|
| Recruiting | 3 | 366 | RoW | RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda | RemeGen Co., Ltd. | Breast Cancer | 06/24 | 12/24 | | |
TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment |
|
|
| Active, not recruiting | 3 | 531 | RoW | JS001, Nab-Paclitaxel, Placebo | Shanghai Junshi Bioscience Co., Ltd. | Triple-Negative Breast Cancer | 12/24 | 12/25 | | |
NCT06323213: Efficacy and Safety Study of 610 in Patients With Severe Asthma |
|
|
| Not yet recruiting | 3 | 480 | NA | 610, Placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Asthma | 06/26 | 09/26 | | |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
| Recruiting | 3 | 314 | RoW | Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Breast Cancer | 07/25 | 01/26 | | |
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia |
|
|
| Recruiting | 3 | 195 | RoW | Orelabrutinib, Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Primary Immune Thrombocytopenia (ITP) | 12/25 | 04/26 | | |
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer |
|
|
| Recruiting | 3 | 350 | RoW | GB491 combined with Letrozole, Placebo combined with Letrozole | Genor Biopharma Co., Ltd. | Breast Cancer | 01/26 | 01/27 | | |
NCT05232149: A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia |
|
|
| Recruiting | 2a/2b | 30 | RoW | Orelabrutinib( lower dose), Orelabrutinib( higher dose) | Beijing InnoCare Pharma Tech Co., Ltd. | Primary Immune Thrombocytopenia | 12/23 | 12/24 | | |
NCT05528679: A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma |
|
|
| Not yet recruiting | 2 | 120 | RoW | 610 100mg, 610 300mg, placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Asthma | 09/23 | 09/23 | | |
NCT06438757: Trial of JYB1904 in Patients With Allergic Asthma |
|
|
| Recruiting | 2 | 60 | RoW | JYB1904, Omalizumab | Jemincare | Allergic Asthma | 10/25 | 10/25 | | |
NCT04835870: Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL |
|
|
| Recruiting | 2 | 78 | RoW | Zanubrutinib, BTK inhibitors, Rituximab, MabThera, Cyclophosphamide, CTX, Doxorubicin, ADM, Vincristine, VCR, Prednisone, Prednisonum | The First Affiliated Hospital of Soochow University | Non-GCB/ABC Diffuse Large B-Cell Lymphoma | 10/25 | 10/25 | | |
| Recruiting | 1/2 | 80 | RoW | TQB3454 Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 06/25 | 12/25 | | |
NCT06122831: A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) |
|
|
| Recruiting | 1/2 | 92 | RoW | TQ05105 Tablets, TQB3617 Capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Myelofibrosis | 12/26 | 04/27 | | |
NCT05584306: A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma |
|
|
| Active, not recruiting | 1 | 24 | RoW | 610 30mg group, 610 100mg group, 610 300mg group, Placebo 30mg group, Placebo 100mg group, Placebo 300mg group | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Asthma | 09/23 | 09/23 | | |
ELPVQFLACS, NCT06517095: Revised Capsular Polishing and Its Impact on the Positioning of the Intraocular Lens and Visual Quality Following Femtosecond Laser-assisted Cataract Surgery |
|
|
| Withdrawn | N/A | 70 | RoW | improved capsular polishing, the conventional I/A polishing | Xi'an People's Hospital (Xi'an Fourth Hospital) | Cataract | 12/25 | 12/25 | | |
NCT04417946: Peer-led Social Media Intervention to Prevent HIV Among Young Men Who Have Sex With Men (YMSM) |
|
|
| Completed | N/A | 227 | US | PrEP messages, Heath messages | Yale University, Substance Abuse and Mental Health Services Administration (SAMHSA) | Pre-Exposure Prophylaxis, Hiv, Men | 04/23 | 04/23 | | |
| Active, not recruiting | N/A | 482 | RoW | | Takeda | Multiple Myeloma, Neoplasms, Plasma Cell | 09/25 | 09/25 | | |
| Fu, Wei M |
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
|
|
| Recruiting | 3 | 711 | Europe, Canada, Japan, US, RoW | Dostarlimab, CAPEOX, FOLFOX | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | 12/28 | 12/30 | | |
NCT05745363: Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer |
|
|
| Recruiting | 1/2 | 20 | RoW | AL2846 capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Differentiated Thyroid Cancer | 06/24 | 12/24 | | |
NCT03943472: BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1 | 10 | RoW | Anti-BCMA CAR-T cells, Fludarabine, Cyclophosphamide, Immune inhibitors | Hrain Biotechnology Co., Ltd., Shanghai Changzheng Hospital | Multiple Myeloma | 11/21 | 05/22 | | |
NCT03716011: A Postmarket Clinical Trial for EXCROSSAL Stent in CAD Patients With 3-month DAPT or 12-month DAPT |
|
|
| Not yet recruiting | N/A | 2700 | RoW | EXCROSSAL | JW Medical Systems Ltd | Coronary Artery Disease | 12/21 | 12/25 | | |
NCT05103748: Function Evaluation of Older Patients With Vertigo and Intervention Study of New Rehabilitation Methods |
|
|
| Recruiting | N/A | 226 | RoW | Traditional vestibular rehabilitation, Cognitive and vestibular dual task training | Xijing Hospital | Vertigo | 08/22 | 12/23 | | |
GIANT, NCT04765592: Guo's Aortic Arch Reconstruction :The Prospective ,Multiple Center Study About the Safety and Efficacy of WeFlow-Arch Modeler Embedded Branch Stent Graft System ( Study) |
|
|
| Active, not recruiting | N/A | 88 | RoW | WeFlow-Arch Modeler Embedded Branch Stent Graft System | Hangzhou Endonom Medtech Co., Ltd. | Aortic Arch Aneurysm | 02/25 | 02/29 | | |
NCT05585060: The Changes in End Expiratory Lung Impedence Measured by EIT and End Expiratory Lung Volume Measured by Passive Expiratory in Controlled Mechanical Ventilated Exacerbation COPD Patients |
|
|
| Recruiting | N/A | 10 | RoW | the changes of end expiratory lung impedence, â–³EELI, the changes of end expiratory lung volume, â–³EELV | The First Affiliated Hospital of Guangzhou Medical University | COPD | 10/23 | 10/23 | | |
